US45258H1068 - Common Stock
IMMIX BIOPHARMA INC
NASDAQ:IMMX (3/28/2024, 8:17:25 PM)
3.07
0 (0%)
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 9 full-time employees. The company went IPO on 2021-12-16. Its lead asset, IMX-110, is in Phase Ib/IIa clinical trials for solid tumors in the United States and Australia. IMX-110 is a negatively charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor (which inhibits multiple kinases simultaneously) and induces tumor cell death with an apoptosis inducer (which activates apoptosis, a non-inflammatory programmed cell death pathway), leveraging its TME Normalization Technology, delivered deep into the tumor micro-environment (TME). Its TME Normalization Technology allows its drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its other drug candidates include IMX-111 and IMX-120. IMX-111 and IMX-120 are under development for colorectal cancer and inflammatory bowel disease.
IMMIX BIOPHARMA INC
11400 West Olympic Blvd., Suite 200
Los Angeles CALIFORNIA
P: 18889581084
Employees: 9
Website: https://www.immixbio.com/
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a...
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words...
LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell...
Here you can normally see the latest stock twits on IMMX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: